Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
FAAH Pipeline<br />
64<br />
FAAH blockers are a very new class<br />
of drugs, as currently <strong>the</strong>re are only<br />
two drugs from this group in <strong>the</strong> clinic.<br />
Both are owned by sanofi-aventis,<br />
which began clinical testing in March<br />
2006 (SSR411298) and February<br />
2007 (SSR 101010). No data about<br />
ei<strong>the</strong>r of <strong>the</strong>se trials has been<br />
released to date.<br />
Defined Health analysis<br />
Compound<br />
SSR 101010<br />
SSR411298<br />
KDS 4103<br />
ORG 231295<br />
OL-135<br />
FAAH Inhibitor<br />
JNJ 2883315<br />
JNJ 1661010<br />
RN-A<br />
RN-B<br />
FAAH Inhibitor<br />
Adis R&D Insight<br />
© Defined Health, 2009<br />
Pain Insight Briefing<br />
Developer<br />
sanofi-aventis<br />
sanofi-aventis<br />
Schering-Plough<br />
Schering-Plough<br />
Adolor Corporation<br />
Vernalis<br />
Johnson & Johnson<br />
Johnson & Johnson<br />
Evotec AG<br />
Evotec AG<br />
Infinity/Purdue/Mundipharma<br />
Phase<br />
I<br />
I<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Preclinical<br />
Indications<br />
Anxiety disorders, depression<br />
Anxiety disorders, depression<br />
Anxiety, depression, and pain<br />
Anxiety, depression, and pain<br />
Inflammatory pain<br />
Neuropathic pain<br />
Neuropathic pain<br />
Neuropathic pain<br />
Chronic pain<br />
Chronic pain<br />
Neuropathic pain
Change language